SRR13311162
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.450
- INTERFERON_ALPHA_RESPONSE+0.430
- P53_PATHWAY+0.410
- HEDGEHOG_SIGNALING+0.360
- NOTCH_SIGNALING+0.360
- WNT_BETA_CATENIN_SIGNALING+0.340
- TNFA_SIGNALING_VIA_NFKB+0.310
- ANGIOGENESIS+0.290
- APOPTOSIS+0.270
- ESTROGEN_RESPONSE_EARLY+0.270
Top 10 suppressed
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.470
- MYC_TARGETS_V1-0.420
- PANCREAS_BETA_CELLS-0.380
- MYC_TARGETS_V2-0.360
- SPERMATOGENESIS-0.360
- MTORC1_SIGNALING-0.260
- CHOLESTEROL_HOMEOSTASIS-0.150
- UNFOLDED_PROTEIN_RESPONSE-0.150
- MITOTIC_SPINDLE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3SQ-01A-21R-A22U-07 | — | — | 0.866 |
| 2 | R66 | — | — | 0.866 |
| 3 | BSR_03_0053_A6_S70 | — | A | 0.848 |
| 4 | SRR13780273 | — | cohortMD2 | 0.838 |
| 5 | TCGA-BH-A0DE-01A-11R-A115-07 | — | A | 0.837 |
| 6 | SRR5088824 | — | — | 0.834 |
| 7 | SRR8518124 | — | D | 0.832 |
| 8 | BS_EYSS0ZDS | low-grade glioma | — | 0.832 |
| 9 | BS_ZV9Z3SY6 | pilocytic astrocytoma | — | 0.831 |
| 10 | TCGA-A1-A0SD-01A-11R-A115-07 | — | A | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.410 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |